A monomolecular coagonist (tirzepatide) of receptors for both incretin hormones (glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide) produced HbA1c values below 5.7% in 50% of the treated patients and weight losses exceeding 20% in obese individuals
Dose changes can make a meaningful difference
doi: 10.3389/fphar.2025.1539411 Received 04 December 2024 Accepted 17 February 2025 Published 10 March 2025 Volume 16 - 2025 Edited by Dongwei Zhang, Beijing University of Chinese Medicine, China Reviewed by Sandeep Kumar, University of Alabama at Birmingham, United States Antonella Al Refaie, University of Siena, Italy Updates Copyright 2025 Tian, Liu, Bao and Li
How Semaglutide Compares to Other Incretin Research Peptides Storage and Reconstitution Before Opening Pull the vial from -20C and let it sit at room temperature for 10 to 15 minutes
New York: Josiah Macy Foundation